Metachromatic Leukodystrophy (MLD) is an autosomal recessive inherited disease and one of the most common lysosomal storage disorders. Mutations in the arylsulfatase A (ARSA) or saposin B (SAP-B) gene lead to abnormal accumulation of sulfatides, causing demyelination of brain white matter and peripheral nerves. It is a neurodegenerative metabolic disease. Its typical pathological feature is symmetrical butterfly-shaped lesions in the white matter of the cerebral hemispheres, while subcortical U-fibers are usually preserved.
MLD is mainly divided into late-infantile, juvenile and adult types. In the early stage, peripheral nerve damage is often the first manifestation, accompanied by central nervous system symptoms. Clinical diagnosis requires a combination of urine metachromatic granule detection, ARSA enzyme activity assay and characteristic white matter lesions on brain MRI; brain MRI is especially valuable for excluding pure peripheral neuropathy. Some patients may develop peripheral neuropathy before neurodegenerative symptoms appear.
Currently available treatments include enzyme replacement therapy, hematopoietic stem cell transplantation and gene therapy. Among them, lentiviral-modified hematopoietic stem cell gene therapy (HSCGT) has been proven to have long-term efficacy, delaying disease progression in late-symptomatic juvenile MLD patients and improving their quality of life.